Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Sherri Jackson

Internal Medicine Richmond, VA Medical Doctor

NPI 1235346495 CMS profile 683526

2200 Pump Rd, Suite 200, Richmond, VA 23233

Open in the dashboard

General payments

$3,482

233 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Sherri Jackson of Richmond, VA is reported in the CMS Open Payments database as having received $3,482 across 233 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $24 1
2023 General $214 11
2022 General $397 23
2021 General $1,109 82
2020 General $1,009 65
2019 General $728 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sherri Jackson
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sherri Jackson were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sherri Jackson Internal Medicine median Middle half National median
2019 $728 $159 $48–$570 $163
2020 $1,009 $119 $33–$402 $114
2021 $1,109 $135 $37–$521 $132
2022 $397 $141 $42–$496 $149
2023 $214 $149 $45–$519 $160
2024 $24 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Amarin Pharma Inc. $528 33 payments
  2. Novo Nordisk Inc $474 38 payments
  3. AbbVie, Inc. $417 25 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $241 17 payments
  5. GlaxoSmithKline, LLC. $180 7 payments
  6. Amgen Inc. $176 13 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $176 16 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $114 7 payments
  9. Pfizer Inc. $113 8 payments
  10. Esperion Therapeutics, Inc. $103 6 payments
  11. Other $959 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $3,482 233 payments
Products named General payments · program years 2019–2024
  1. Vascepa $492 31 payments
  2. Ozempic $385 31 payments
  3. UBRELVY $293 18 payments
  4. RYBELSUS $292 24 payments
  5. XIFAXAN $241 17 payments
  6. TRINTELLIX $151 14 payments
  7. Prolia $110 8 payments
  8. TRULANCE $103 8 payments
  9. NEXLETOL $103 6 payments
  10. TRELEGY ELLIPTA $102 2 payments
  11. Other $2,215 148 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

437

Median for Internal Medicine: 777

Drug cost

$4,374

Median for Internal Medicine: $73,373

Branded share of claims

7.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Atorvastatin Calcium Generic 76 $585
Olmesartan Medoxomil Generic 20 $527
Pravastatin Sodium Generic 36 $478
Valsartan Generic 12 $439
Losartan Potassium Generic 38 $411
Levothyroxine Sodium Generic 42 $409
Valsartan-Hydrochlorothiazide Valsartan/Hydrochlorothiazide Brand 13 $264
Amlodipine Besylate Generic 45 $220
Escitalopram Oxalate Generic 11 $208
Rosuvastatin Calcium Generic 19 $175

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

233 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record